Nuclear oncology : from pathophysiology to clinical applications / / Duccio Volterrani [and four others], editors

• Pubblicazione: Cham, Switzerland : , : Springer, , [2022]; ©2022
• Edizione: Third edition.
• Descrizione fisica: 1 online resource (2241 pages)
• Disciplina: 616.99407575
• Soggetto topico: Cancer - Radionuclide imaging; Cancer - Radiotherapy; Nuclear medicine
• Persona (resp. second.): VolterraniDuccio
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Intro -- Preface to the Third Edition -- Preface to the Second Edition -- Preface to the First Edition -- Acknowledgments -- Contents -- About the Editors -- Contributors -- Part I: Basic Science -- 1 Cancer Biology of Molecular Imaging -- Introduction -- The Evolving Context of Molecular Imaging: Cancer Genomics and Epigenomics -- Hallmarks of Cancer -- The Tumor Mass -- Imaging the Tumor Mass -- Neovasculature -- Hypoxia -- Cellular Constituents and Cell-Cell Synergism of the Tumor Mass -- Immune Cell Cancer Immunotherapy -- Immune Checkpoint Blockade -- Imaging the Immune T Cells -- The Metastatic Process -- Imaging the Cancer Cell -- Total Lesion Glycolysis (TLG) as a Predictive Marker of Prognosis and Tumor Responsiveness -- Proliferation Imaging -- 18F-FLT Imaging of Proliferation After Chemotherapy -- The Cancer Biology of Cellular Lineage Plasticity and the Nuclear Imaging Phenotype -- Lineage Plasticity and Relevance to Molecular Imaging in Prostate Cancer -- Molecular Imaging of Fibroblast-Activating Protein, a Molecule Expressed in Tumor Stroma -- Oncogene and Non-oncogene Addiction -- Examples of Imaging the Action Driver Mutations in Cancer Cells Indirectly Through the Effects on Metabolism -- BRAF Inhibition in Advanced Melanoma with V600E Mutation -- Inhibition of MEK, a Downstream Signal Transduction Molecule in the RAS/BRAF/ERK Pathway, Can Reverse 131I Resistance in Patie... -- Future Applications -- References -- 2 Principles of Molecular Targeting for Radionuclide Therapy -- Introduction -- The Choice of Radionuclide -- Nuclear Properties -- Radioisotope Production -- Theranostics -- Instrument Resolution and Biological Resolution -- Radiobiological Properties Affecting the Choice of Radionuclide -- Radiation Microdosimetry and Particle Range -- The Choice of a Chemical Platform -- Salts and Covalent Bonds -- Chelating Agents. ; Coordination of Tc(V) and Re(V) -- Nanoparticles -- Location of the Target: The Challenges of Designing Radiotracers for Intracellular Compartments -- Critical Subcellular Sites of Interaction with Ionizing Radiation (Direct Effects) -- Radiation-Induced Biological Bystander Effects (RIBBEs) -- Critical Subcellular Sites of Interaction with Ionizing Radiation (Indirect Effects) -- Cell Membrane -- Mitochondria -- Transfectant Mosaic Spheroid Model -- Transfectant Mosaic Xenograft Model -- Media Transfer -- LET and Dose Rate -- Conclusion -- References -- 3 Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications -- Introduction -- 99mTc-Labeled Radiopharmaceuticals -- 99mTc-Sodium Pertechnetate -- 99mTc-Diphosphonates -- 99mTc-Radiocolloids -- 99mTc-Magroaggregated Albumin -- 99mTc-Sestamibi -- 99mTc-Tetrofosmin -- 99mTc-EDDA/HYNIC-Octreotide or Octreotate -- Lung Ventilation Radiopharmaceuticals -- 99mTc-DTPA -- 99mTc-Technegas -- Xenon-133 -- Xenon-127 -- Radioiodinated Agents -- Sodium Iodide -- Radioiodinated Metaiodobenzylguanidine -- 201Tl-Chloride -- 111In-Pentetreotide -- 111In-Capromab Pendetide -- 67Ga-Citrate -- Suggested Readings -- 4 Positron-Emitting Radiopharmaceuticals for Diagnostic Applications in Oncology -- Introduction -- Positron-Emitting Radionuclides -- Carbon-11 (11C) -- Nitrogen-13 (13N) -- Oxygen-15 (15O) -- Fluorine-18 (18F) -- Copper-64 (64Cu) -- Gallium-68 (68Ga) -- Rubidium-82 (82Rb) -- PET Radiopharmaceuticals -- Deoxy-[18F]fluoro-d-glucose -- Nitrogen-13 Ammonia -- Oxygen-15 Water -- Rubidium-82 Chloride -- [11C]Methionine and Other Tracers for Protein Synthesis -- Choline-Based Tracers for Phospholipid Synthesis -- Fluorine-18 Fluciclovine -- Gallium-68 PSMA Ligands -- Fluorine-18 Sodium Fluoride -- Fluorine-18 Misonidazole and Other Hypoxia Tracers. ; Fluorine-18 Fluorothymidine and Other Substrates for DNA Synthesis -- Fluorine-18 DOPA and Other Amine Precursors -- Gallium-68 DOTATOC, Copper-64 DOTATATE, and Other Somatostatin Analogs -- Suggested Readings -- 5 Radiopharmaceuticals for Therapy -- Background -- Alpha-Particle Emitters -- Radium-223 (223Ra) -- Auger Electron Emitters -- Emitters of β- Particles -- Iodine-131 (131I) -- Yttrium-90 (90Y) -- Lutetium-177 (177Lu) -- Samarium-153 (153Sm) -- Strontium-89 (89Sr) -- Rhenium-186 (186Re) and Rhenium-188 (188Re) -- Phosphorus-32 (32P) -- Holmium-166 (166Ho) -- Treatment of Thyroid Disease with 131I-Iodide -- Treatment of Neuroendocrine Neoplasms Originating from the Neural Crest with [131I]MIBG -- Peptide Receptor Radionuclide Therapy -- Bone-Seeking Radiopharmaceuticals and Prostate Cancer -- Radioimmunotherapy for Hematologic Malignancies -- Radionuclide Therapy of Primary and Metastatic Liver Tumors -- Suggested Readings -- 6 Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications -- Introduction and Background -- Peptide Receptor Targeting -- 99mTc-EDDA/HYNIC-TOC -- 99mTc-PSMA-Ligands -- 99mTc-CAIX -- Apoptosis -- 99mTc-Annexin V -- 99mTc-Duramycin -- Angiogenesis -- 99mTc-HYNIC-VEGF -- Integrins -- 99mTc-αP2 -- 99mTc-NC100692 (or 99mTc-Maraciclatide) -- 99mTc-3PRGD2 -- 99mTc-RGD-BBN -- Hybrid Radioactive/Fluorescent RGD -- Agents Targeting the Extracellular Matrix -- 99mTc-AP39 -- Matrix Metalloproteinases -- Epidermal Growth Factor Receptor (EGFR) -- 99mTc-ADAPT6 -- Folate Receptor Overexpression -- 99mTc-HYNIC-folate -- References -- 7 Novel Positron-Emitting Radiopharmaceuticals -- Introduction -- Targeting Cellular Transport and Metabolism -- Overview -- Imaging Amino Acid Transport and Metabolism -- [11C]Methionine -- O-(2-[18F]Fluoroethyl)-L-Tyrosine ([18F]FET). ; 3,4-Dihydroxy-6-[18F]Fluorophenylalanine ([18F]FDOPA) -- 18F-Labeled Glutamine -- Imaging Lipid Biosynthesis -- Targeting Cell Surface Receptors -- Overview -- Imaging the Expression of Integrins -- Imaging the Expression of Gastrin-Releasing Peptide Receptors -- ImmunoPET Imaging -- ImmunoPET of HER2 -- ImmunoPET of EGFR -- ImmunoPET of PD-1/PD-L1 -- Targeting the Tumor Microenvironment -- Overview -- Imaging Tumor Hypoxia -- Imaging Tumor Acidosis -- Radiotheranostics -- Overview -- Targeting Somatostatin Receptors -- Targeting Prostate-Specific Membrane Antigen -- Radioimmunotherapy -- Concluding Remarks -- References -- 8 Novel Radiopharmaceuticals for Therapy -- Introduction -- Alpha-Emitting Agents -- Radium-223 (223Ra) -- Astatine-211 (211At) -- Actinium-225 (225Ac) -- Thorium-227 (227Th) -- Bismuth-213 (213Bi) -- Lead-212 (212Pb) -- Agents Emitting β- Particles -- Iodine-131 (131I) -- Lutetium-177 (177Lu) -- Holmium-166 (166Ho) -- Ytterbium-175 (175Yb) -- Samarium-153 (153Sm) -- Thulium-170 (170Tm) -- Copper-67 (67Cu) -- Yttrium-90 (90Y) -- Gold-198 (198Au) -- Promethium-149 (149Pm) -- Rhodium-105 (105Rh) -- Other Radionuclides -- Concluding Remarks -- References -- 9 Physics of Nuclear Oncology -- Structure of the Atom -- Energy and Mass -- Energy and Frequency -- Energy and Mass -- Radioactivity and Radiation -- Electromagnetic Radiation -- X-Rays -- Gamma Radiation (γ) -- Annihilation Radiation (γ±) -- Particulate Radiations -- Alpha Radiation (α) -- Beta Radiation (β-) -- β- Dosimetry -- Positron Decay (β+) and Electron Capture (EC) -- Auger Electrons -- Isomeric Transition (IT) and Internal Conversion (IC) -- Radioactive Decay -- Interaction of Radiation with Matter -- Interaction of Particulate Radiation with Matter -- Interaction of Photons with Matter -- Photoelectric Effect -- Compton Scattering -- Pair Production. ; Attenuation and Scattering of Photons -- Photon Attenuation -- Radionuclides Used in Nuclear Oncology -- References -- 10 Instrumentation for Positron Emission Tomography -- Introduction -- Basic Physics and Technology of PET -- Scintillation Crystals -- Silicon Photomultiplier (SiPM)-Based Scintillation Detectors -- Time-of-Flight (TOF) PET -- Total-Body PET -- PET/MRI -- Concluding Remarks -- References -- 11 Instrumentation for Single-Photon Emission Computed Tomography (SPECT) -- Introduction -- Radiation Detectors for SPECT -- Radionuclides for SPECT -- Gamma Camera Design -- SPECT Data-Acquisition -- Data ``Corrections´´ and Activity Quantitation -- Image Reconstruction -- Commercial Devices -- Concluding Remarks -- References -- 12 Instrumentation for Intraoperative Detection and Imaging -- Introduction -- Nuclear Counting and Imaging -- Optical and Near-Infrared (NIR) Imaging -- Cerenkov Imaging -- Photoacoustic Imaging -- Diffuse Optical Tomography -- Optical Coherence Tomography -- Raman Spectroscopic Imaging -- Intraoperative US, CT, and MRI -- Concluding Remarks -- References -- 13 Radiobiology and Radiation Dosimetry in Nuclear Medicine -- Introduction -- Radiobiology -- Conventional Radiobiological Models -- Cell Death Mechanisms -- Possible Contributing Mechanisms to RNT Tumor Responses -- Low-Dose/Dose-Rate Apoptosis -- Low-Dose Hyper-radiosensitivity-Increased Radioresistance -- G2 Synchronization, Bystander, and Cross-Fire Effects -- Adaptive Responses -- Fractionated RNT and Hypoxia -- Future Directions -- Dosimetry: Overview on Methods -- Clinical Experience -- 131I-Iodide Therapy of Differentiated Thyroid Carcinoma -- Peptide Receptor Radionuclide Therapy -- Radioimmunotherapy of Lymphoma -- Dosimetry in the Radioembolization of Liver Tumors -- Therapy of Neuroectodermal Neuroendocrine Malignancies. ; Treatment of Metastatic Bone Pain.
• Titolo autorizzato: Nuclear Oncology
• ISBN: 3-031-05494-6
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910616204703321
• Lo trovi qui: Univ. Federico II